ERBB2 and breast carcinoma: The prevalence rate for HER2-low breast cancer ranges from 45% to 55% of all breast cancers, with a higher prevalence in patients with estrogen receptor (ER)-positive cancer than in those with triple-negative breast cancer (TNBC)4 (45.9% versus 29.4%).5